In METEOR, a phase 3 trial, Cabozantinib treatment was associated with PFS and OS improvement compared with Everolimus in patients with advanced RCC, who progressed after previous VEGFR TKI [56,57], and was approved for this population. This evidence concerns the gene KDR and renal cell carcinoma.